CA3249464A1 - Antisense antibacterial compounds and methods - Google Patents

Antisense antibacterial compounds and methods

Info

Publication number
CA3249464A1
CA3249464A1 CA3249464A CA3249464A CA3249464A1 CA 3249464 A1 CA3249464 A1 CA 3249464A1 CA 3249464 A CA3249464 A CA 3249464A CA 3249464 A CA3249464 A CA 3249464A CA 3249464 A1 CA3249464 A1 CA 3249464A1
Authority
CA
Canada
Prior art keywords
methods
antibacterial compounds
antisense antibacterial
antisense
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3249464A
Other languages
English (en)
Inventor
Bruce L Geller
David Greenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon State University
University of Texas System
University of Texas at Austin
Original Assignee
Oregon State University
University of Texas System
University of Texas at Austin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon State University, University of Texas System, University of Texas at Austin filed Critical Oregon State University
Publication of CA3249464A1 publication Critical patent/CA3249464A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA3249464A 2014-12-31 2015-12-23 Antisense antibacterial compounds and methods Pending CA3249464A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462098713P 2014-12-31 2014-12-31
CA2972653A CA2972653C (en) 2014-12-31 2015-12-23 ANTIBACTERIAL COMPOUNDS, ANTISENSE, AND PROCESSES

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2972653A Division CA2972653C (en) 2014-12-31 2015-12-23 ANTIBACTERIAL COMPOUNDS, ANTISENSE, AND PROCESSES

Publications (1)

Publication Number Publication Date
CA3249464A1 true CA3249464A1 (en) 2025-11-29

Family

ID=56285129

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3249464A Pending CA3249464A1 (en) 2014-12-31 2015-12-23 Antisense antibacterial compounds and methods
CA2972653A Active CA2972653C (en) 2014-12-31 2015-12-23 ANTIBACTERIAL COMPOUNDS, ANTISENSE, AND PROCESSES

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2972653A Active CA2972653C (en) 2014-12-31 2015-12-23 ANTIBACTERIAL COMPOUNDS, ANTISENSE, AND PROCESSES

Country Status (7)

Country Link
US (1) US11293024B2 (OSRAM)
EP (1) EP3240794A4 (OSRAM)
JP (2) JP6994941B2 (OSRAM)
AU (1) AU2015372560B2 (OSRAM)
CA (2) CA3249464A1 (OSRAM)
HK (1) HK1246303A1 (OSRAM)
WO (1) WO2016108930A2 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2948373A1 (en) 2014-05-16 2015-11-19 Oregon State University Antisense antibacterial compounds and methods
AU2015264449B2 (en) 2014-05-19 2022-05-05 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
US11293024B2 (en) 2014-12-31 2022-04-05 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
EP3394262B1 (en) 2015-12-23 2024-08-28 Oregon State University Antisense antibacterial compounds and methods
EP3394261A4 (en) 2015-12-23 2019-11-27 Oregon State University ANTIBACTERIAL ANTISENSE COMPOUNDS AND METHOD
US20210324394A1 (en) * 2018-08-17 2021-10-21 Centre National De La Recherche Scientifique (Cnrs) Rna-based biocontrol methods to protect plants against pathogenic bacteria and / or promote beneficial effects of symbiotic and commensal bacteria
GB2579253A (en) 2018-11-28 2020-06-17 Pedanius Therapeutics Ltd Antibacterial antisense agents

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5668616A (en) * 1979-11-08 1981-06-09 Yukio Kimura Preparation of antibiotic composition
US5521063A (en) 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
JP2528107B2 (ja) 1985-03-15 1996-08-28 サマ−トン，ジエ−ムス ポリヌクレオチド測定試薬と方法
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US5166315A (en) 1989-12-20 1992-11-24 Anti-Gene Development Group Sequence-specific binding polymers for duplex nucleic acids
US5185444A (en) 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5217866A (en) 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
WO1993001286A2 (en) 1991-06-28 1993-01-21 Massachusetts Institute Of Technology Localized oligonucleotide therapy
PT1704878E (pt) 1995-12-18 2013-07-17 Angiodevice Internat Gmbh Composições de polímeros reticulados e métodos para a sua utilização
US6245747B1 (en) 1996-03-12 2001-06-12 The Board Of Regents Of The University Of Nebraska Targeted site specific antisense oligodeoxynucleotide delivery method
CA2289878A1 (en) * 1997-05-02 1998-11-12 University Of Guelph Proteins involved in the synthesis and assembly of core lipopolysaccharide of pseudomonas aeruginosa
WO2000015265A1 (en) * 1998-09-16 2000-03-23 Vitagenix, Inc. Compositions and methods of use of uptake mechanisms for diagnostic and therapeutic applications of oligonucleotides targeting bacteria
US20040033972A1 (en) * 2000-12-20 2004-02-19 Horwitz Marcus A. Treatment of mycobacterium tuberculosis with antisense polynucleotides
US20060241075A1 (en) 2001-05-18 2006-10-26 Sirna Therapeutics, Inc. RNA interference mediated inhibition of desmoglein gene expression using short interfering nucleic acid (siNA)
US20040029129A1 (en) 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
AU2004231740A1 (en) 2003-04-17 2004-11-04 The Trustees Of Columbia University In The City Ofnew York Desmoglein 4 is a novel gene involved in hair growth
EP1629105B1 (en) 2003-04-29 2010-09-01 AVI BioPharma, Inc. Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
WO2006085973A2 (en) * 2004-07-02 2006-08-17 Avi Biopharma, Inc. Antisense antibacterial method and compound
US20070154896A1 (en) 2005-02-11 2007-07-05 International Business Machines Corporation System and method for identification of MicroRNA target sites and corresponding targeting MicroRNA sequences
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
AU2006267051B2 (en) 2005-07-13 2013-03-07 Sarepta Therapeutics, Inc. Antisense antibacterial method and compound
US7790694B2 (en) 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
WO2007025016A1 (en) 2005-08-25 2007-03-01 Texas Tech University System Inhibition of metallo-beta-lactamase by double-stranded dna
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2009005793A2 (en) 2007-06-29 2009-01-08 Avi Biopharma, Inc. Tissue specific peptide conjugates and methods
CA2704261C (en) 2007-11-15 2015-05-26 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
US8076476B2 (en) 2007-11-15 2011-12-13 Avi Biopharma, Inc. Synthesis of morpholino oligomers using doubly protected guanine morpholino subunits
US8299206B2 (en) 2007-11-15 2012-10-30 Avi Biopharma, Inc. Method of synthesis of morpholino oligomers
WO2009139635A1 (en) * 2008-05-15 2009-11-19 Prosensa Technologies B.V. Polymyxin derivatives and uses thereof
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
WO2011018798A2 (en) 2009-08-14 2011-02-17 Indian Association For The Cultivation Of Science Morpholino-based antisense agent
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
JP5831455B2 (ja) 2010-09-30 2015-12-09 日本新薬株式会社 モルホリノ核酸誘導体
WO2012064991A1 (en) * 2010-11-12 2012-05-18 Avi Biopharma, Inc. Antisense antibacterial compounds and methods
US20120213663A1 (en) 2011-02-23 2012-08-23 King Fahd University Of Petroleum And Minerals Method of removing e. coli bacteria from an aqueous solution
JP6478632B2 (ja) 2011-05-05 2019-03-06 サレプタ セラピューティクス， インコーポレイテッド ペプチドオリゴヌクレオチドコンジュゲート
US9161948B2 (en) * 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
KR101317263B1 (ko) 2011-07-05 2013-10-10 (주)지노첵 리얼타임 ｐｃｒ을 이용한 카바페넴 내성 장내균 검사 방법 및 키트
WO2013011072A1 (en) 2011-07-20 2013-01-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Carbapenemase and antibacterial treatment
AU2012340390B2 (en) * 2011-11-18 2016-11-24 Sarepta Therapeutics, Inc. Functionally-modified oligonucleotides and subunits thereof
KR101450751B1 (ko) * 2012-07-05 2014-10-16 서강대학교산학협력단 미생물을 이용한 지방산 제조 방법
CA2948373A1 (en) 2014-05-16 2015-11-19 Oregon State University Antisense antibacterial compounds and methods
AU2015264449B2 (en) 2014-05-19 2022-05-05 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
US11293024B2 (en) 2014-12-31 2022-04-05 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
EP3394261A4 (en) 2015-12-23 2019-11-27 Oregon State University ANTIBACTERIAL ANTISENSE COMPOUNDS AND METHOD
EP3394262B1 (en) 2015-12-23 2024-08-28 Oregon State University Antisense antibacterial compounds and methods

Also Published As

Publication number Publication date
CA2972653A1 (en) 2016-07-07
EP3240794A2 (en) 2017-11-08
JP2022040131A (ja) 2022-03-10
AU2015372560B2 (en) 2021-12-02
CA2972653C (en) 2025-05-06
US20190169609A1 (en) 2019-06-06
WO2016108930A2 (en) 2016-07-07
US11293024B2 (en) 2022-04-05
HK1246303A1 (zh) 2018-09-07
AU2015372560A1 (en) 2017-07-20
EP3240794A4 (en) 2018-10-31
WO2016108930A3 (en) 2016-08-25
JP6994941B2 (ja) 2022-02-04
JP2018506272A (ja) 2018-03-08

Similar Documents

Publication Publication Date Title
PL3215147T3 (pl) Związki norketaminy osłabiającej działanie układu nerwowego i sposoby
IL248856A0 (en) New treatment
EP3143141A4 (en) Antisense antibacterial compounds and methods
EP3146047A4 (en) Antisense antibacterial compounds and methods
IL251107A0 (en) Compounds and methods
CA3249464A1 (en) Antisense antibacterial compounds and methods
GB201416716D0 (en) Use
GB201402267D0 (en) Antibacterial agents
GB201416727D0 (en) Use
GB201522311D0 (en) Use
GB201522309D0 (en) Use
IL250405A0 (en) Antibacterial sideromycins
EP3194628A4 (en) Antisense compounds and uses thereof
GB201521085D0 (en) Use
GB201518466D0 (en) Use
EP3194591A4 (en) Antisense compounds and uses thereof
GB201510077D0 (en) Use
GB201411027D0 (en) Treatment
GB201412411D0 (en) Treatment
GB201522443D0 (en) Use
GB201522411D0 (en) Use
GB201404301D0 (en) Compounds and combinations
GB201515987D0 (en) Use
GB201514770D0 (en) Compounds and their use
GB201418134D0 (en) Bandage